Effect of human serum on de-N-acetyl sialic acid epitope expression and antibody activity against N. meningitidis group B

Vaccine

Volumn 28, Issue 37, 2010, Pages 5967-5972

  Flitter, Becca A ^a   Ing, Jessica Y ^a,b   Moe, Gregory R ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bactericidal activity; De N acetyl sialic acid; Neisseria meningitidis; Polysialic acid

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SEAM 12; MONOCLONAL ANTIBODY SEAM 2; MONOCLONAL ANTIBODY SEAM 3; NEURAMINIC ACID CONTAINING POLYSIALIC ACID ANTIBODY; POLYCLONAL ANTIBODY; POLYSIALIC ACID; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; COMPLEMENT; SIALIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BACTEREMIA; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIOLYSIS; CONTROLLED STUDY; HUMAN; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAT; SERUM; ANIMAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; SERUM BACTERICIDAL ACTIVITY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; EPITOPES; HUMANS; MICE; NEISSERIA MENINGITIDIS, SEROGROUP B; RATS; SIALIC ACIDS;

EID: 77955508945     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.119     Document Type: Article

References (32)

1. Granoff D.M., Feavers I.M., Borrow R. Meningococcal vaccines. Vaccines 2004, 959-988. Saunders, Philadelphia, Pa. 4th ed. S.A.O. Plotkin, A. Walter (Eds.).
2. Jodar L., Feavers I., Salisbury D., Granoff D.M. Development of vaccines against meningococcal disease. Lancet 2002, 359:1499-1508.
3. Hayrinen J., Jennings H., Raff H.V., Rougon G., Hanai N., Gerardy-Schahn R., et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 1995, 171(6):1481-1490.
4. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(8346):355-357.
5. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22(9-10):1087-1096.
6. Jennings H.J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 1986, 137(5):1708-1713.
7. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest 1979, 63(5):836-848.
8. Courtney A.H., Puffer E.B., Pontrello J.K., Yang Z.Q., Kiessling L.L. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc Natl Acad Sci USA 2009, 106(8):2500-2505.
9. Moe G.R., Bhandari T.S., Flitter B.A. Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against Neisseria meningitidis groups B and C. J Immunol 2009, 182(10):6610-6617.
10. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(1):501-510.
11. Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009, 77(2):764-769.
12. Chou H.H., Takematsu H., Diaz S., Iber J., Nickerson E., Wright K.L., et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 1998, 95(20):11751-11756.
13. Granoff D.M., Bartoloni A., Ricci S., Gallo E., Rosa D., Ravenscroft N., et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998, 160(10):5028-5036.
14. Moe G.R., Dave A., Granoff D.M. Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect Immun 2005, 73(4):2123-2128.
15. Moe G.R., Dave A., Granoff D.M. Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Mol Immunol 2006, 43(9):1424-1431.
16. Seid R, inventor Chiron S.r.l., assignee. Neisseria meningitidis serogroup B Glycoconjugates. US patent no. 6,638,513; 2003.
17. Moe G.R., Granoff D.M. Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Intern Rev Immunol 2001, 20:201-221.
18. Moe G.R., Tan S., Granoff D.M. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol Med Microbiol 1999, 26(3-4):209-226.
19. Stephens D.S., Swartley J.S., Kathariou S., Morse S.A. Insertion of Tn916 in Neisseria meningitidis resulting in loss of group B capsular polysaccharide. Infect Immun 1991, 59(11):4097-4102.
20. Martin D.R., Ruijne N., McCallum L., O'Hallahan J., Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13(4):486-491.
21. Fossa da Paz M., Baruque-Ramos J., Hiss H., Vicentin M.A., Leal M.B., Raw I. Polysaccharide production in batch process of Neisseria meningitidis serogroup C comparing Frantz, modified Frantz and Catlin 6 cultivation media. Braz J Micro 2003, 34:27-32.
22. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
23. Toropainen M., Kayhty H., Saarinen L., Rosenqvist E., Hoiby E.A., Wedege E., et al. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine 1999, 17(20-21):2677-2689.
24. Moe G.R., Tan S., Granoff D.M. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999, 67(11):5664-5675.
25. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188(11):1730-1740.
26. Moe G.R., Zuno-Mitchell P., Hammond S.N., Granoff D.M. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 2002, 70(11):6021-6031.
27. Moe G.R., Zuno-Mitchell P., Lee S.S., Lucas A.H., Granoff D.M. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun 2001, 69(6):3762-3771.
28. Plested J.S., Welsch J.A., Granoff D.M. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 2009, 16(6):785-791.
29. Jarvis G.A., Vedros N.A. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun 1987, 55(1):174-180.
30. Kahler C.M., Martin L.E., Shih G.C., Rahman M.M., Carlson R.W., Stephens D.S. The (alpha2→8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun 1998, 66(12):5939-5947.
31. Varki A. Sialic acids as ligands in recognition phenomena. FASEB J 1997, 11(4):248-255.
32. Manzi A.E., Sjoberg E.R., Diaz S., Varki A. Biosynthesis and turnover of O-acetyl and N-acetyl groups in the gangliosides of human melanoma cells. J Biol Chem 1990, 265(22):13091-13103.